CTLA4 and cancer: demonstrated that treatment of mice bearing carcinogen-induced OPLs with a CD40 agonist decreased the incidence of invasive cancers more potently than any of the other immunotherapies evaluated, including treatment with an anti-PD-1 antibody as single agent or in combined with an anti-CTLA-4 antibody.